Cornell Stamoran

@stamoran

25+ yrs pharma. Strategist, futurist, & advocate. Drug delivery, patient outcomes, innovation, M&A. My opinions only! Medicine Maker 2019 Power List

Northeast US
Vrijeme pridruživanja: svibanj 2011.

Tweetovi

Blokirali ste korisnika/cu @stamoran

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @stamoran

  1. proslijedio/la je Tweet
    29. sij

    A Nobel Prize winning plenary and $79/night on the Strip in Las Vegas at the Paris Hotel? :-0 We aren't done yet. Stay tuned....and get your abstracts submitted. You do NOT want to miss this.

    Poništi
  2. proslijedio/la je Tweet
    26. sij

    Randomized trials are expensive First, there is the cost of the RCT Then, there is all the lost earnings on drugs that don't work, but could have been approved via uncontrolled trials.

    Poništi
  3. proslijedio/la je Tweet
    26. sij

    IMHO: the secret to biotech investing is to back mgmt teams with experience in clinical development. There’s a huge difference between academic research and making a drug. Many of the successful biotechs in Boston right now are full of vets from Millennium, Biogen, Vertex, etc.

    Poništi
  4. proslijedio/la je Tweet

    Sorry, but I'm calling bullsh*t on this. After 25 years in Kendall Sq, I am now happily ensconced in Waltham and never going back. Much more efficient with time and money and fewer distractions. But I will acknowledge that maybe I'm just a cranky old man.

    Poništi
  5. proslijedio/la je Tweet
    25. sij

    "New Jersey has been at the center of medical innovation for well over a century – and remains so. We are fortunate to be represented by 14 federal legislators who recognize this and also are all strongly committed – as is our biopharmaceutical sector – to patients..."

    Poništi
  6. proslijedio/la je Tweet
    25. sij

    #5 The FDA has devalued the gold standard on R&D. And that threatens everyone in drug development

    Poništi
  7. proslijedio/la je Tweet
    25. sij

    Dr. Christopher Booth reminds us about the endpoints that matter—live longer and live better

    Poništi
  8. proslijedio/la je Tweet
    25. sij

    . has his work cut out for him. I am very close to 50/50 on this issue. I think our instinct is to say “of course entrepreneurship is good!” But there are many reasons to leave it to non-academics. This will be a must-see event in Vegas.

    Poništi
  9. proslijedio/la je Tweet
    24. sij

    Sorry to hear of the death of Clayton Christensen. Inspiration for years, but in Dec 2016 he really started me thinking about "health assurance" - healthcare offers nothing unless you become sick, he said Suppose you thought bigger than that ... ?

    Poništi
  10. proslijedio/la je Tweet
    25. sij

    This is a consistent finding across many studies. Men MDs ALWAYS accept more industry $$$ than women MDs. Anyone have thoughts as to the reasons/mechanisms? I’d honestly be totally speculating.

    Poništi
  11. proslijedio/la je Tweet
    25. sij

    Bingo. Our best weapons against cancer are not magic bullets

    Poništi
  12. proslijedio/la je Tweet
    24. sij

    BS alert: projects therapies will cost $3B to $9B annually from 2020-24 Highly misleading! - Only 0.5% to 1.6% of total US spending - Ignores offsets from lower spending - Disregards value to patients

    Poništi
  13. proslijedio/la je Tweet
    24. sij

    Wait! I’m confused. Are you saying there are real offsets associated with these therapies??? Can’t wait to see the empirical data supporting this claim! Please send my way

    Poništi
  14. proslijedio/la je Tweet
    24. sij

    Terrific topic and terrific stars that will collide at annual meeting! Join us for in Las Vegas!

    Poništi
  15. proslijedio/la je Tweet
    24. sij

    main event: Stars Collide debate between vs. . "Is entrepreneurship good or bad for academia?" What do you think? Should academic engineers personally translate their work? Or stick to their science talents?

    Poništi
  16. proslijedio/la je Tweet
    17. sij

    The lashing sent White House staff scrambling to organize a meeting on drug pricing this morning. Officials now believe a long-awaited drug pricing proposal hated by the GOP establishment could have new life:

    Prikaži ovu nit
    Poništi
  17. proslijedio/la je Tweet
    14. sij

    If gene therapy can provide a cure to a disease e.g. HepC, then the economics of providing a cure have to be figured into the pricing discussion. Let the race begin! First Movers will corner the markets. #

    Poništi
  18. proslijedio/la je Tweet
    15. sij

    It is interesting how much head shaking I've heard on this one. Consensus I'm getting on the square is that it won't work. Interesting experiment, won't work.

    Poništi
  19. proslijedio/la je Tweet
    14. sij

    My favorite moment at so far was watching a panel of four white men talk about the importance of diversity.

    Poništi
  20. proslijedio/la je Tweet
    15. sij
    Odgovor korisnicima

    tramadol was approved 25 years ago. celecoxib was approved 22 years ago.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·